Sio Gene Therapies (Sio Gene Therapies) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Sio Gene Therapies Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sio Gene Therapies's annualized Gross Profit for the quarter that ended in Dec. 2022 was $0.00 Mil. Sio Gene Therapies's average Total Assets over the quarter that ended in Dec. 2022 was $50.51 Mil. Therefore, Sio Gene Therapies's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 was 0.00%.

Sio Gene Therapies Gross-Profit-to-Asset % Historical Data

The historical data trend for Sio Gene Therapies's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sio Gene Therapies Gross-Profit-to-Asset % Chart

Sio Gene Therapies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

Sio Gene Therapies Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sio Gene Therapies's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Sio Gene Therapies's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sio Gene Therapies's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's Gross-Profit-to-Asset % falls into.

Sio Gene Therapies Gross-Profit-to-Asset % Calculation

Sio Gene Therapies's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2022 )	/	( (Total Assets (A: Mar. 2021 )	+	Total Assets (A: Mar. 2022 ))	/ count )
	=	0	/	( (135.147	+	75.08)	/ 2 )
	=	0	/	105.1135
	=	0.00 %

Sio Gene Therapies's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2022 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Dec. 2022 ))	/ count )
	=	0	/	( (53.746	+	47.272)	/ 2 )
	=	0	/	50.509
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Sio Gene Therapies Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sio Gene Therapies (Sio Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

130 West 42nd Street, 26th Floor, New York, NY, USA, 10036

Website

https://www.siogtx.com

Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.

Executives

Parag V Meswani	officer: Chief Commercial Officer	130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu	officer: Chief Executive Officer	C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif	officer: Principal Financial Officer	C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo	10 percent owner	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado	10 percent owner	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc	10 percent owner	1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901